Population Health Investment Co., Inc.
PHICU
NASDAQ Capital Market10.03
USD
-0.02
- -
CIK
0001825724
ISIN
KYG717161239
Return %
Stock
S&P500
1Y
0.91
26.53
3Y
-0.30
76.60
5Y
-0.30
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- One World Financial Center New York City NY United States of America 10281
- IPO Date
- Nov 18, 2020
- CIK
- 0001825724
- Similar Companies
- Business
- Population Health Investment Co., Inc. (PHICU) operates as a blank check company, or special purpose acquisition company (SPAC), whose primary purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, with a focus on the healthcare industry, particularly therapeutics companies in the United States and other developed countries; it currently conducts no significant operations and generates no revenues. The company offers no core products or services beyond its structure for pursuing such business combinations, including the issuance of Class A ordinary shares and redeemable warrants traded separately on Nasdaq under symbols PHIC and PHICW following the separation of its initial public offering units. Founded in 2020 and headquartered at One World Financial Center in New York, New York, it targets healthcare sectors globally but with emphasis on developed markets and maintains a board with expertise in biopharmaceutical investing and strategy. In a major development, the company announced in November 2022 that it would redeem all outstanding public Class A ordinary shares effective November 30, 2022, at approximately $10.09 per share, cease trading on Nasdaq, liquidate its trust account, and dissolve without consummating an initial business combination, as required by its governing documents after failing to complete a transaction within the mandated timeframe; warrants expired worthless, and no further operations or distributions occurred post-liquidation. No subsequent mergers, acquisitions, partnerships, funding rounds, or strategic shifts have been reported as of late 2025, confirming the company's defunct status following dissolution.
U.S. IPO Weekly Recap: Breast Cancer Biotech Pops 158% In A 6-IPO Week